viernes, 3 de julio de 2020

Remdesivir's controversial cost, early vaccine data, and AI at the end of life

Remdesivir's controversial cost, early vaccine data, and AI at the end of life

Daily Recap

Listen: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life

By DAMIAN GARDE AND REBECCA ROBBINS


In this episode, we dig into the long-awaited price for remdesivir and the disparate reactions to it from lawmakers, analysts, and activists.

No hay comentarios: